Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts hav...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2021-11-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/26/11/10.52586/5024 |
| _version_ | 1818355054938161152 |
|---|---|
| author | Hui Xuan Lim Masita Arip Abdul Aziz Al-Fattah Yahaya Seyed Davoud Jazayeri Sibrandes Poppema Chit Laa Poh |
| author_facet | Hui Xuan Lim Masita Arip Abdul Aziz Al-Fattah Yahaya Seyed Davoud Jazayeri Sibrandes Poppema Chit Laa Poh |
| author_sort | Hui Xuan Lim |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. Three COVID-19 vaccines (BNT162b2, mRNA-1273 and Sputnik V) in clinical Phase III trials have now achieved >90% efficacy in preventing COVID-19. Since SARS-CoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world’s population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed. |
| first_indexed | 2024-12-13T19:35:13Z |
| format | Article |
| id | doaj.art-4b7a2409a5ae453db394e65357972d24 |
| institution | Directory Open Access Journal |
| issn | 2768-6701 |
| language | English |
| last_indexed | 2024-12-13T19:35:13Z |
| publishDate | 2021-11-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj.art-4b7a2409a5ae453db394e65357972d242022-12-21T23:33:50ZengIMR PressFrontiers in Bioscience-Landmark2768-67012021-11-0126111286130410.52586/5024s2768-6701(21)00068-XImmunogenicity and safety of SARS-CoV-2 vaccines in clinical trialsHui Xuan Lim0Masita Arip1Abdul Aziz Al-Fattah Yahaya2Seyed Davoud Jazayeri3Sibrandes Poppema4Chit Laa Poh5Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, MalaysiaAllergy and Immunology Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, MalaysiaCentre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, MalaysiaCentre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, MalaysiaSchool of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, MalaysiaCentre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, MalaysiaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. Three COVID-19 vaccines (BNT162b2, mRNA-1273 and Sputnik V) in clinical Phase III trials have now achieved >90% efficacy in preventing COVID-19. Since SARS-CoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world’s population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed.https://www.imrpress.com/journal/FBL/26/11/10.52586/5024immunogenicitysafetysars-cov-2vaccines |
| spellingShingle | Hui Xuan Lim Masita Arip Abdul Aziz Al-Fattah Yahaya Seyed Davoud Jazayeri Sibrandes Poppema Chit Laa Poh Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials Frontiers in Bioscience-Landmark immunogenicity safety sars-cov-2 vaccines |
| title | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_full | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_fullStr | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_full_unstemmed | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_short | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_sort | immunogenicity and safety of sars cov 2 vaccines in clinical trials |
| topic | immunogenicity safety sars-cov-2 vaccines |
| url | https://www.imrpress.com/journal/FBL/26/11/10.52586/5024 |
| work_keys_str_mv | AT huixuanlim immunogenicityandsafetyofsarscov2vaccinesinclinicaltrials AT masitaarip immunogenicityandsafetyofsarscov2vaccinesinclinicaltrials AT abdulazizalfattahyahaya immunogenicityandsafetyofsarscov2vaccinesinclinicaltrials AT seyeddavoudjazayeri immunogenicityandsafetyofsarscov2vaccinesinclinicaltrials AT sibrandespoppema immunogenicityandsafetyofsarscov2vaccinesinclinicaltrials AT chitlaapoh immunogenicityandsafetyofsarscov2vaccinesinclinicaltrials |